Optimising an innovative xenograft model for inoculation of myeloma cell lines

Abstract

Introduction: Multiple myeloma (MM) is a haematological condition characterised by abnormal proliferation of plasma cells in the bone marrow. The disease progresses from an asymptomatic phase to MM. Testing drugs preclinically is crucial for developing novel therapies, and the chick embryo xenograft chorioallantoic membrane (CAM) model is gaining popularity compared to other models. Methods: Gelatin was used as a matrix for delivering MM cell lines onto the CAM to mimic tumour growth and facilitate drug testing. Gelatin concentrations of 10%, 8%, and 6% were prepared, and the RPMI 8226 cell line was chosen for experiments. Fertilised hen eggs were prepared for incubation, and on embryonic development day 7 (EDD7), RPMI 8226 MM cells mixed with gelatin were implanted on the CAM. On EDD14, the CAM was excised for histological analysis. Results: In vitro viability analysis demonstrated that 6% and 8% gelatin concentrations were most favourable for cell retention. On EDD14, angiogenic responses and tumour growth were observed. Histological analysis confirmed the presence of plasma cell growth on the CAM. The 8% gelatin concentration had the highest number of vessels, indicating angiogenesis, and also showed good viability. Conclusion: The CAM model combined with gelatin as a delivery matrix shows promise for studying MM and testing novel therapies. Future studies may explore other extracellular matrix components.</p